NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
A combination of pharmacological and genetic studies in mice confirmed that the Y1 and Y5 receptors mediate the potent orexigenic actions of exogenous NPY. Although the physiological role of NPY in causing obesity is less clear, potent and selective antagonists of both Y1 and Y5 have been developed. Some of the NPY antagonists have suitable pharmacokinetic (PK) properties that allowed them to be evaluated in various rodent models of obesity. Several different Y1 and Y5 antagonists cause weight loss in rodent models, though confirmation that these effects are mechanism based has been limited. One Y5 antagonist, MK-0557 was evaluated in a 1-yr clinical trial and found to cause modest weight loss. Optimal NPY antagonist therapeutics for obesity may require blockade of both the Y1 and Y5 receptors.
MacNeil
Douglas J
DJ
Merck Research Laboratories, 80M-213, Rahway, NJ 07065, USA. doug_macneil@merck.com
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology
D019440:Anti-Obesity Agents; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; C100568:neuropeptide Y5 receptor